Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The profitability metrics exhibited considerable fluctuation over the observed period, spanning from March 2022 to December 2025. A general trend of declining margins is apparent, particularly in the latter half of the period, although some metrics show signs of stabilization or modest recovery towards the end of the timeframe. Return on Equity (ROE) demonstrates significant volatility, while Return on Assets (ROA) displays a more consistent, albeit declining, pattern.
- Gross Profit Margin
- The gross profit margin began at 73.30% in March 2022 and generally remained above 72% through September 2022. A noticeable decline commenced in December 2022, falling to 68.60%, and continued through June 2024, reaching a low of 61.56%. A slight recovery is observed from June 2024 onwards, culminating in 65.75% by December 2025, but remains significantly below the initial levels.
- Operating Profit Margin
- The operating profit margin showed initial strength, peaking at 39.31% in September 2022. A consistent downward trend followed, with a substantial drop to 29.35% by December 2022. This decline accelerated through June 2024, reaching 19.97%. A modest recovery is evident in the final quarters, increasing to 25.83% by December 2025, but still represents a considerable decrease from earlier values.
- Net Profit Margin
- The net profit margin mirrored the trends observed in the gross and operating profit margins. Starting at 23.42% in March 2022, it peaked at 27.88% in September 2022 before entering a period of decline. The most significant drop occurred between September 2023 and March 2024, falling from 29.52% to 13.35%. A partial recovery is seen in the later quarters, reaching 21.94% by December 2025, but remains substantially lower than the initial levels.
- Return on Equity (ROE)
- ROE exhibited the most dramatic fluctuations. It began at an exceptionally high level of 624.78% in March 2022, followed by a steep decline throughout the year, reaching 178.97% by December 2022. The volatility continued, with ROE falling to 69.59% by December 2024, before showing a recovery to 89.06% by December 2025. The initial value appears to be an outlier, making trend analysis challenging.
- Return on Assets (ROA)
- ROA demonstrated a more consistent, though still downward, trend. Starting at 9.67% in March 2022, it gradually decreased to 6.91% by December 2022. The decline continued through March 2024, reaching 4.05%. A slight improvement is observed in the final quarters, with ROA increasing to 8.51% by December 2025, but remains below the initial levels.
In summary, the observed period is characterized by a general erosion of profitability margins, coupled with significant volatility in ROE and a consistent decline in ROA. While some metrics show signs of stabilization or modest recovery towards the end of the period, the overall trend suggests increasing pressure on profitability.
Return on Sales
Return on Investment
Gross Profit Margin
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Gross profit from product sales | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Gross profit margin = 100
× (Gross profit from product salesQ4 2025
+ Gross profit from product salesQ3 2025
+ Gross profit from product salesQ2 2025
+ Gross profit from product salesQ1 2025)
÷ (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The gross profit margin exhibited fluctuations over the observed period, beginning in March 2022 and extending through December 2025. Initially, the margin demonstrated relative stability, followed by a noticeable decline and subsequent partial recovery.
- Initial Stability (Mar 31, 2022 – Dec 31, 2022)
- From March 31, 2022, to December 31, 2022, the gross profit margin remained consistently high, fluctuating between 73.30% and 74.17%. This period indicates a stable relationship between product sales revenue and the cost of goods sold.
- Downward Trend (Mar 31, 2023 – Dec 31, 2023)
- Beginning in March 2023, a downward trend in the gross profit margin became apparent. The margin decreased from 73.65% in March 2023 to 68.60% by December 2023. This suggests increasing costs of goods sold relative to product sales, or potentially pricing pressures.
- Continued Decline and Stabilization (Mar 31, 2024 – Dec 31, 2024)
- The decline continued into the first half of 2024, reaching a low of 58.71% in June 2024. However, the margin showed signs of stabilization in the latter half of the year, increasing to 59.85% in December 2024. This suggests that the factors contributing to the decline may have begun to moderate.
- Recovery and Final Period (Mar 31, 2025 – Dec 31, 2025)
- A recovery in the gross profit margin was observed throughout 2025. The margin increased from 61.48% in March 2025 to 65.75% in December 2025. This indicates improved cost management or increased pricing power during this period. The final value of 65.75% represents a substantial increase from the low point in June 2024, but remains below the levels observed in 2022 and early 2023.
The gross profit from product sales generally increased over the period, but the fluctuations in the gross profit margin suggest that the rate of increase in sales revenue did not consistently outpace the rate of increase in the cost of product sales. The most significant decline in margin coincided with a substantial increase in product sales in the latter part of 2023, indicating potential cost pressures associated with scaling production or changes in product mix.
Operating Profit Margin
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Operating income | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Operating profit margin = 100
× (Operating incomeQ4 2025
+ Operating incomeQ3 2025
+ Operating incomeQ2 2025
+ Operating incomeQ1 2025)
÷ (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The operating profit margin exhibited fluctuations over the observed period, beginning in March 2022 and extending through December 2025. An initial period of relative strength was followed by a notable decline, with subsequent partial recoveries and stabilization.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The operating profit margin commenced at 32.78% and demonstrated an increasing trend, peaking at 39.31% by September 30, 2022. While experiencing some variability, the margin remained above 38% throughout this timeframe, suggesting strong operational performance. A slight decrease to 38.57% was observed by the end of 2022.
- Decline and Initial Recovery (Mar 31, 2023 – Jun 30, 2023)
- A significant downward trend began in the first quarter of 2023, with the operating profit margin falling to 36.07%. This decline continued into the second quarter, reaching a low of 29.35% by December 31, 2023. A partial recovery was then noted in the first half of 2024, with the margin increasing to 20.96% and 19.97% respectively.
- Stabilization and Improvement (Sep 30, 2024 – Dec 31, 2025)
- From September 30, 2024, the operating profit margin showed signs of stabilization and improvement. The margin increased from 19.97% to 22.66% by the end of 2024, and continued to rise through 2025, reaching 25.83% by December 31, 2025. This suggests a potential return to more favorable operational efficiencies or pricing power.
- Correlation with Product Sales
- While not the primary focus, a review of product sales alongside the operating profit margin reveals a complex relationship. Product sales generally increased over the period, however, the operating profit margin did not consistently follow this trend. The decline in margin during 2023 occurred despite increasing product sales, indicating potential pressures on cost of goods sold or increased operating expenses. The later stabilization and improvement in margin coincided with continued sales growth, suggesting improved cost management or pricing strategies.
In summary, the operating profit margin experienced a period of strength, followed by a substantial decline, and then a gradual recovery towards the end of the analyzed timeframe. The fluctuations suggest sensitivity to factors beyond revenue generation, such as cost control and operational efficiency.
Net Profit Margin
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net profit margin = 100
× (Net income (loss)Q4 2025
+ Net income (loss)Q3 2025
+ Net income (loss)Q2 2025
+ Net income (loss)Q1 2025)
÷ (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The net profit margin exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. An initial upward trend is apparent in the first half of 2022, followed by relative stability before a significant shift in performance emerges in late 2023 and early 2024.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The net profit margin began at 23.42% and increased to a peak of 27.88% in September 2022, before slightly decreasing to 26.42% by the end of the year. This period demonstrates a generally healthy and stable profitability level.
- Growth Phase (Mar 31, 2023 – Sep 30, 2023)
- A substantial increase is observed in the net profit margin, reaching 31.77% in March 2023. This upward momentum continued, albeit at a slower pace, reaching 29.52% by September 2023. This suggests improved operational efficiency or favorable pricing dynamics during this timeframe.
- Significant Decline (Dec 31, 2023 – Mar 31, 2024)
- A dramatic decline in the net profit margin is evident, falling to 24.96% in December 2023 and further decreasing to a low of 13.35% in March 2024. This represents a substantial erosion of profitability and warrants further investigation into potential contributing factors, such as increased costs, pricing pressures, or unfavorable product mix.
- Recovery and Stabilization (Jun 30, 2024 – Dec 31, 2025)
- Following the decline, the net profit margin began a recovery, reaching 13.58% in September 2024 and 12.77% in December 2024. This trend continued into 2025, with the margin increasing to 18.10% in March, 19.75% in June, 20.31% in September, and culminating in 21.94% by December 2025. This indicates a successful effort to restore profitability, although the margin did not return to the levels seen in the first half of 2023.
Overall, the period demonstrates a cyclical pattern of profitability, with initial strength, a period of growth, a sharp decline, and subsequent recovery. The substantial decrease in profitability during late 2023 and early 2024 is a key area of concern, but the subsequent recovery suggests successful corrective actions were implemented.
Return on Equity (ROE)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| ROE1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
ROE = 100
× (Net income (loss)Q4 2025
+ Net income (loss)Q3 2025
+ Net income (loss)Q2 2025
+ Net income (loss)Q1 2025)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The Return on Equity (ROE) exhibited substantial fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values were exceptionally high, followed by a marked decline and subsequent instability.
- Initial High Values & Subsequent Decline (Mar 31, 2022 – Dec 31, 2022)
- ROE began at 624.78% in March 2022, representing a significantly elevated return. This was followed by a substantial decrease to 271.85% in June 2022, continuing downward to 187.11% and 178.97% in subsequent quarters, ending the year at 178.97%. This indicates a rapid normalization from an initially unsustainable level.
- Continued Downward Trend & Stabilization (Mar 31, 2023 – Dec 31, 2023)
- The downward trend persisted into the first half of 2023, reaching 117.67% in June 2023. A slight recovery was observed in the latter half of the year, with ROE reaching 107.78% in December 2023, suggesting a potential stabilization, albeit at a considerably lower level than the initial period.
- Volatility & Recent Performance (Mar 31, 2024 – Dec 31, 2025)
- The period from March 2024 through December 2025 demonstrates significant volatility. ROE decreased sharply to 74.93% in March 2024, followed by a substantial increase to 56.20% in June 2024, then 69.59% in December 2024. This pattern continued into 2025, with ROE reaching 95.59% in March, 89.11% in June, 72.82% in September, and concluding at 89.06% in December 2025. This suggests a period of fluctuating profitability relative to equity.
The considerable variation in ROE throughout the period warrants further investigation into the underlying drivers of net income and stockholders’ equity. The initial exceptionally high ROE values may be attributable to specific, non-recurring events, while the subsequent fluctuations likely reflect changes in operational performance and capital structure.
Return on Assets (ROA)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Net income (loss) | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||
| ROA1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
ROA = 100
× (Net income (loss)Q4 2025
+ Net income (loss)Q3 2025
+ Net income (loss)Q2 2025
+ Net income (loss)Q1 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The Return on Assets (ROA) exhibited fluctuating performance over the analyzed period, spanning from March 31, 2022, to December 31, 2025. Initial values demonstrated a generally strong profitability relative to asset base, followed by a period of decline and subsequent recovery.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- ROA values began at 9.67% and peaked at 11.09% in June 2022, before moderating to 10.06% by the end of 2022. This indicates a consistently healthy level of profitability in relation to total assets during this timeframe. The fluctuations suggest some quarterly variability in earnings or asset utilization.
- Decline (Mar 31, 2023 – Dec 31, 2023)
- A noticeable downward trend emerged in 2023. ROA decreased from 8.92% in March 2023 to a low of 6.91% in December 2023. This decline coincided with an increase in total assets, suggesting that earnings growth did not keep pace with asset expansion. The lowest point, 6.91%, represents a significant decrease from the highs observed in the prior year.
- Recovery and Stabilization (Mar 31, 2024 – Dec 31, 2025)
- Beginning in March 2024, ROA began to recover, reaching 7.53% in June 2024 and further improving to 8.51% by December 2025. While there were intermediate fluctuations, the overall trend indicates a strengthening of profitability relative to the asset base. The ROA in December 2025, at 8.51%, remains below the peaks observed in 2022 but represents a substantial improvement from the lows of 2023. The value of 4.05% in March 2024 represents the lowest point in the entire period.
- Overall Trend
- The ROA demonstrates a cyclical pattern. A period of strong performance was followed by a decline, and then a recovery. The recovery, while positive, did not fully restore ROA to its earlier levels. The increase in total assets throughout the period appears to have influenced the ROA, as earnings did not consistently grow at the same rate.
The observed fluctuations in ROA warrant further investigation into the underlying drivers of net income and asset utilization to understand the factors contributing to these trends.